BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 31112749)

  • 1. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
    Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
    Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).
    Gaumann AK; Drexler HC; Lang SA; Stoeltzing O; Diermeier-Daucher S; Buchdunger E; Wood J; Bold G; Breier G
    Int J Oncol; 2014 Dec; 45(6):2267-77. PubMed ID: 25340839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
    Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
    Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.
    Tseng FJ; Chen YC; Lin YL; Tsai NM; Lee RP; Chung YS; Chen CH; Liu YK; Huang YS; Hwang CH; Lai YK; Liao KW
    Cancer Biol Ther; 2010 Nov; 10(9):865-73. PubMed ID: 20818186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2.
    Jiang J; Xu K; Wang L; Xin W; Zhao G; Huang M; Li S; Luan X; Fang J
    Eur J Pharm Sci; 2018 Aug; 121():251-259. PubMed ID: 29715501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
    Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
    Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis.
    Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J
    Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
    Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
    Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
    Kim KL; Suh W
    Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
    Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
    Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib Ameliorated Retinal Neovascularization by Suppressing PDGFR-α and PDGFR-β.
    Zhou L; Sun X; Huang Z; Zhou T; Zhu X; Liu Y; Wang J; Cheng B; Li M; He C; Liu X
    Cell Physiol Biochem; 2018; 48(1):263-273. PubMed ID: 30007969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.
    Shibuya M
    J Biochem; 2013 Jan; 153(1):13-9. PubMed ID: 23172303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRbeta.
    Zhong L; Guo XN; Zhang XH; Sun QM; Tong LJ; Wu ZX; Luo XM; Jiang HL; Nan FJ; Zhang XW; Lin LP; Ding J
    Cancer Biol Ther; 2006 Mar; 5(3):323-30. PubMed ID: 16575201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth.
    Chung TW; Kim SJ; Choi HJ; Kwak CH; Song KH; Suh SJ; Kim KJ; Ha KT; Park YG; Chang YC; Chang HW; Lee YC; Kim CH
    J Mol Med (Berl); 2013 Feb; 91(2):271-82. PubMed ID: 22935775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.